Evidence map›Paper›PMID 32056091›Full record

ReviewDigestive diseases and sciences2020

Autism Spectrum Disorder as a Brain-Gut-Microbiome Axis Disorder.

Virginia Saurman, Kara G Margolis, Ruth Ann Luna

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06514573 (Effects of a Postbiotic Supplementation on Gastrointestinal and Core Symptoms in Autism Spectrum Disorder), which is not on this map. Cited by 69 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 5 pooled it
25.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06514573 narecruitingnot on this mapstarted 2025, after this paper: background citation

Effects of a Postbiotic Supplementation on Gastrointestinal and Core Symptoms in Autism Spectrum Disorder: A Multicenter Randomized Controlled Trial

TypeinterventionalSponsorIstituto Superiore di SanitàRan2025 to 2026Enrolled128ConditionsAutism Spectrum Disorder (ASD)ArmsSodium Butyrate, Placebo (cornstarch)
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 5 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Microbiota in Autism Spectrum Disorder: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Virginia SaurmanDepartment of Pediatrics, Columbia University Medical Center, 620 West 168th Street, New York, NY, 10032, USA.
Kara G MargolisDepartment of Pediatrics, Columbia University Medical Center, 620 West 168th Street, New York, NY, 10032, USA.
Ruth Ann LunaDepartment of Pathology and Immunology, Texas Children's Microbiome Center, Baylor College of Medicine, Texas Children's Hospital, Feigin Tower, 1102 Bates Avenue, Suite 955, Houston, TX, 77030, USA. raluna@bcm.edu.
Columbia University Irving Medical Center · USTexas Children's Hospital · US

Funding

MICROENVIRONMENT IN ENTERIC NEURON DEVELOPMENTR01NS015547 · NINDS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI GERSHON, MICHAEL D, MARGOLIS, KARA GROSS · 1985 to 2022
$7.2M
Linkage of s100a10 (p11) to enteric 5-HT4-mediated serotonergic signaling roles in GI motility, enteric nervous system development, and co-morbid dysfunction of gut and brainR01DK126644 · NIDDK · NEW YORK UNIVERSITY · PI MARGOLIS, KARA GROSS · 2021 to 2024
$1.9M
NIDDK NIH HHS R01 DK126644NINDS NIH HHS R01 NS015547
6 · The paper itself

Abstract

While there are numerous medical comorbidities associated with ASD, gastrointestinal (GI) issues have a significant impact on quality of life for these individuals. Recent findings continue to support the relationship between the gut microbiome and both GI symptoms and behavior, but the heterogeneity within the autism spectrum requires in-depth clinical characterization of these clinical cohorts. Large, diverse, well-controlled studies in this area of research are still needed. Although there is still much to discover about the brain-gut-microbiome axis in ASD, microbially mediated therapies, specifically probiotics and fecal microbiota transplantation have shown promise in the treatment of GI symptoms in ASD, with potential benefit to the core behavioral symptoms of ASD as well. Future research and clinical trials must increasingly consider complex phenotypes in ASD in stratification of large datasets as well as in design of inclusion criteria for individual therapeutic interventions.

Indexed as

Gastrointestinal MicrobiomeAnimalsAutism Spectrum DisorderBrainFecal Microbiota TransplantationGastrointestinal DiseasesGastrointestinal TractHumansProbioticsAutism spectrum disordersBrain-gut axisGastrointestinalMicrobiome

Identifiers

PMID32056091
PMCPMC7580230
OpenAlexW3006262715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.